electroCore to Present at Major European Headache Meeting (EHMTIC) on the Success of Its Non-Invasive Vagus Nerve …

BASKING RIDGE, N.J.–(BUSINESS WIRE)– This weekend, at the international headache meeting in Copenhagen (EHMTIC*), electroCore will be presenting full data on their PREVA study, a randomized, multi-center trial across several European countries, which showed that preventative use of non-invasive vagus nerve stimulation (nVNS) can substantially reduce the frequency of cluster headache attacks (i.e., by 43.4%) versus the control group (the current standard of care, which experienced only a 12% reduction). Three poster presentations will provide full details of the PREVA trial and include A report on – the randomized phase A report on the open label phase An analysis of quality of life impact On Saturday evening electroCore is hosting a satellite symposium with three eminent headache specialists. Professor Jean Schoen, Director of the Headache Research Unit at the University of Liège, Belgium, who will provide an overview of Neuromodulation and the role of non-invasive vagus nerve (nVNS) stimulation. Dr. Charly Gaul, Director of the Migraine and Headache Clinic Königstein, Germany and the principle investigator of the PREVA trial who will comprehensively explore the use of nVNS in the prevention of cluster headache. Professor Stephen Silberstein, Director of the Thomas Jefferson Headache Centre at the Thomas Jefferson University and Hospitals Philadelphia, who will present data on nVNS in the prevention of chronic migraine. electroCore, a US based company, has developed non-invasive Vagus Nerve Stimulation (nVNS) therapies, which are self-administered by patients for the treatment of multiple conditions in neurology, psychiatry, respiratory and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in gastric motility disorders and epilepsy. In Europe, electroCore’s nVNS technology has a CE mark for primary headache, bronchoconstriction, epilepsy, gastric motility disorders, and anxiety and depression. It also has regulatory approval for the acute and/or prophylactic treatment of cluster headache, migraine and medication overuse headache in South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia, and in Canada for cluster headache. US approval is anticipated in 2015. www.electrocoremedical.com *European Headache and Migraine and Trust International Congress Note to Editors: electroCore was founded in 2005 and is based in New Jersey, USA. The therapy is currently being launched through healthcare professionals in Canada, Germany, UK, and other parts of Europe with US approval anticipated in 2015. HealthDisease & Medical Conditionscluster headache


Vane Percy & RobertsSimon Vane Percy(T) +44 (0) 1737 821890(e) [email protected]

The post electroCore to Present at Major European Headache Meeting (EHMTIC) on the Success of Its Non-Invasive Vagus Nerve … appeared first on Posts Headache.


    Download your FREE Report on Headache


    Just a sneak peek…

    • Guide to cluster headache
    • Why do you get a headache?
    • Headache and migraine pain relief through hypnotherapy
    • Can stress cause severe headache?
    • Caffeine: the culprit behind our migraines
    • Menopause and headaches
    • Sinusitis: how serious is it?
    Download It Completely FREE

    Just Insert Your Name and email

    We will also send you a Complimentary copy of our Headache Newsletter. Our newsletter subscription has the latest information on Headache and Migraine treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on Headache


    Worried about Headache and Migraine? You can have now information about the latest treatments and medical research. All this and more in our Headache Newsletter.slide11t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.


    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!